Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)

25 May 2017

Abstract excerpt

INTRODUCTION: Acute myelogenous leukemia (AML) is a heterogeneous group of malignancies driven by genetic mutations and deregulated epigenetic control. Relapse/refractory disease remains frequent in younger patients and even more so in older patients, including treatment with epigenetic drugs in this age group, mainly with hypomethylating agents. New treatment strategies are urgently needed. The recent discovery...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28541716
DOI: 10.1080/13543784.2017.1335711

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)PMID 28541716Read ↗

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasmsSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical ApplicationsSemantic proximity Read ↗

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospectsSemantic proximity Read ↗

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AMLSemantic proximity Read ↗

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinationsSemantic proximity Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

Domain-selective targeting of BET proteins in cancer and immunological diseasesSemantic proximity Read ↗

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute LeukemiaSemantic proximity Read ↗

A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia CellsSemantic proximity Read ↗

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemiaSemantic proximity Read ↗

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.